Lyra Therapeutics Inc (LYRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 398 | 1,534 | 1,558 | 1,363 | 285 |
| Gross Profit | 398 | 1,534 | 1,558 | 1,363 | 285 |
| Operating Expenses | 31,420 | 97,882 | 68,678 | 57,669 | 43,900 |
| Operating Income | -31,022 | -96,348 | -67,120 | -56,306 | -43,615 |
| Other Income | 2,114 | 2,952 | 4,499 | 1,041 | 102 |
| Pre-tax Income | -28,908 | -93,396 | -62,621 | -55,265 | -43,513 |
| Income Tax | 11 | 39 | 59 | 13 | N/A |
| Net Income Continuous | -28,919 | -93,435 | -62,680 | -55,278 | -43,513 |
| Net Income | $-28,919 | $-93,435 | $-62,680 | $-55,278 | $-43,513 |
| EPS Basic Total Ops | -18.62 | -71.75 | -63.00 | -91.50 | -167.50 |
| EPS Basic Continuous Ops | -18.62 | -71.76 | -62.93 | -91.41 | -167.54 |
| EPS Diluted Total Ops | -18.62 | -71.75 | -63.00 | -91.50 | -167.50 |
| EPS Diluted Continuous Ops | -18.62 | -71.76 | -62.93 | -91.41 | -167.54 |
| EPS Diluted Before Non-Recurring Items | -18.62 | -49.00 | -61.50 | -91.50 | -167.50 |
| EBITDA(a) | $-30,563 | $-98,153 | $-70,338 | $-55,731 | $-42,614 |